Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 3, 2009

Response Genetics to Support Roche’s Cancer Test Development

  • Roche Diagnostics will use Response Genetics’ PCR analysis platform to assess HER2 gene expression. The accurate measurement of HER2 gene expression can assist with treatment decisions for cancer patients.

    It has been shown that women with HER2-positive gene expression have a three times higher risk of recurrence, even if the cancer is caught in the early stages. HER2 gene amplification has been shown to correlate with improved clinical outcome in response to certain cancer drugs and its measurement by RT PCR was recently shown to correlate with analyses by fluorescence in situ hybridization and immunohistochemistry.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »